A project to test what’s being called an ultrapotent, second-generation COVID-19 vaccine candidate will receive up to $173.4 million to conduct phase 3 clinical trials. The vaccine was developed in… Read More
Genetically editing cells using CRISPR could be the answer to curing genetic disorders such as sickle cell anemia. But in order for the technology to be available for people in… Read More